Filing Details
- Accession Number:
- 0001209191-18-034160
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-05-30 16:49:12
- Reporting Period:
- 2018-05-25
- Accepted Time:
- 2018-05-30 16:49:12
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1492426 | Horizon Pharma Plc | HZNP | Pharmaceutical Preparations (2834) | 272179987 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1641580 | K Brian Beeler | C/O Horizon Pharma Plc Connaught House, 1St Fl, 1 Burlington Rd Dublin L2 4 | Evp, General Counsel | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Acquisiton | 2018-05-25 | 48,000 | $2.40 | 110,524 | No | 4 | M | Direct | |
| Ordinary Shares | Disposition | 2018-05-25 | 17,931 | $16.11 | 92,593 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Ordinary Shares | Stock Option (Right to Buy) | Disposition | 2018-05-25 | 48,000 | $0.00 | 48,000 | $2.40 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2023-01-01 | No | 4 | M | Direct |
Footnotes
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.10 to $16.145 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 25% of the shares subject to the option vested and became exercisable on the first anniversary of the date of grant (1/2/2013), and the remaining shares vested in 36 equal monthly installments thereafter.
Billionaire Hedge Funds
